Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2012
At a glance
- Drugs Boceprevir (Primary) ; Raltegravir
- Indications Hepatitis C; HIV infections
- Focus Pharmacokinetics
- Acronyms OPAL
- 12 Sep 2012 Results published in the Clinical Infectious Diseases.
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 15 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History